{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:25:10Z","timestamp":1778883910143,"version":"3.51.4"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0229768","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T18:29:56Z","timestamp":1583173796000},"page":"e0229768","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Annualized hospitalization rate with natalizumab vs fingolimod in second-line treatment for RRMS in the public healthcare system in Brazil: A claim database approach"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3487-2240","authenticated-orcid":true,"given":"Guilherme Silva","family":"Julian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo Papal\u00e9o","family":"Rosim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estela Cristina","family":"Carneseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9ssica","family":"Rigolon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,3,2]]},"reference":[{"key":"pone.0229768.ref001","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"A Compston","year":"2008","journal-title":"Lancet (London, England)"},{"key":"pone.0229768.ref002","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis","volume":"46","author":"FD Lublin","year":"1996","journal-title":"Neurology"},{"key":"pone.0229768.ref003","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade\u2014Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas da Esclerose M\u00faltipla. 2018. p. 27."},{"key":"pone.0229768.ref004","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.msard.2015.08.004","article-title":"Prevalence of multiple sclerosis in Brazil: A systematic review","volume":"4","author":"ABCN da Gama Pereira","year":"2015","journal-title":"Mult Scler Relat Disord"},{"key":"pone.0229768.ref005","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/1352458509347131","article-title":"Best practice recommendations for the selection and management of patients with multiple sclerosis receiving natalizumab therapy","volume":"15","author":"PK Coyle","year":"2009","journal-title":"Mult Scler J"},{"key":"pone.0229768.ref006","first-page":"44","author":"C Wharf","year":"2013","journal-title":"Assessment report"},{"key":"pone.0229768.ref007","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.2147\/NDT.S114636","article-title":"The use of natalizumab for multiple sclerosis","volume":"13","author":"R Brandstadter","year":"2017","journal-title":"Neuropsychiatr Dis Treat"},{"key":"pone.0229768.ref008","first-page":"29","article-title":"International survey of methods used in health technology assessment (HTA): does practice meet the principles proposed for good research?","volume":"2","author":"JM Stephens","year":"2012","journal-title":"Comp Eff Res"},{"key":"pone.0229768.ref009","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1212\/WNL.0000000000002395","article-title":"Comparative efficacy of fingolimod vs natalizumab","volume":"86","author":"L Barbin","year":"2016","journal-title":"Neurology"},{"key":"pone.0229768.ref010","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1177\/1352458516650736","article-title":"Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies","volume":"22","author":"D Baroncini","year":"2016","journal-title":"Mult Scler J"},{"key":"pone.0229768.ref011","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1177\/1352458514535282","article-title":"An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy","volume":"20","author":"RL Carruthers","year":"2014","journal-title":"Mult Scler J"},{"key":"pone.0229768.ref012","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s00415-016-8343-5","article-title":"Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-na\u00efve patients with multiple sclerosis","volume":"264","author":"L Prosperini","year":"2017","journal-title":"J Neurol"},{"key":"pone.0229768.ref013","unstructured":"Ag\u00eancia Nacional de Sa\u00fade Suplementar. Dados Gerais\u2014ANS\u2014Ag\u00eancia Nacional de Sa\u00fade Suplementar. 2018 [cited 29 Jun 2018]. Available: http:\/\/www.ans.gov.br\/perfil-do-setor\/dados-gerais"},{"key":"pone.0229768.ref014","unstructured":"Conselho Nacional de Sa\u00fade. Resolu\u00e7\u00e3o No 510, de 07 de Abril de 2016. 2016. Available: http:\/\/conselho.saude.gov.br\/resolucoes\/2016\/reso510.pdf"},{"key":"pone.0229768.ref015","first-page":"A1","article-title":"Brazilian Healthcare Record Linkage (BRHC-RLK)\u2013A Record Linkage Methodology For Brazilian Medical Claims Datasets (DATASUS)","volume":"20","author":"D Campos","year":"2017","journal-title":"Value Heal"},{"key":"pone.0229768.ref016","doi-asserted-by":"crossref","first-page":"68","DOI":"10.56645\/jmde.v11i25.431","article-title":"Propensity Scores: A Practical Introduction Using R","volume":"11","author":"A Olmos","year":"2015","journal-title":"J Multidiscip Eval"},{"key":"pone.0229768.ref017","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jacc.2016.10.060","article-title":"Comparison of Propensity Score Methods and Covariate Adjustment: Evaluation in 4 Cardiovascular Studies","volume":"69","author":"MC Elze","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"pone.0229768.ref018","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/ane.12718","article-title":"A longitudinal real-life comparison study of natalizumab and fingolimod","volume":"136","author":"R Lanzillo","year":"2017","journal-title":"Acta Neurol Scand"},{"key":"pone.0229768.ref019","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1468-1331.2008.02519.x","article-title":"Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis","volume":"16","author":"N Putzki","year":"2009","journal-title":"Eur J Neurol"},{"key":"pone.0229768.ref020","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/ana.24339","article-title":"Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis","volume":"77","author":"T Kalincik","year":"2015","journal-title":"Ann Neurol"},{"key":"pone.0229768.ref021","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000361044","article-title":"Are Natalizumab and Fingolimod Analogous Second-Line Options for the Treatment of Relapsing-Remitting Multiple Sclerosis? A Clinical Practice Observational Study","volume":"72","author":"A Gajofatto","year":"2014","journal-title":"Eur Neurol"},{"key":"pone.0229768.ref022","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/ane.12864","article-title":"Real-life clinical use of natalizumab and fingolimod in Austria","volume":"137","author":"M Guger","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"pone.0229768.ref023","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.msard.2019.05.026","article-title":"The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study","volume":"33","author":"E Curti","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"pone.0229768.ref024","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1177\/1352458518768433","article-title":"Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing\u2013remitting multiple sclerosis","volume":"24","author":"J Lorscheider","year":"2018","journal-title":"Mult Scler J"},{"key":"pone.0229768.ref025","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/1352458516643393","article-title":"A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod","volume":"23","author":"N Koch-Henriksen","year":"2017","journal-title":"Mult Scler J"},{"key":"pone.0229768.ref026","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/ane.12718","article-title":"A longitudinal real-life comparison study of natalizumab and fingolimod","volume":"136","author":"R Lanzillo","year":"2017","journal-title":"Acta Neurol Scand"},{"key":"pone.0229768.ref027","first-page":"e0199446","volume-title":"PLoS One","author":"I Maia Diniz","year":"2018"},{"key":"pone.0229768.ref028","doi-asserted-by":"crossref","first-page":"e0208837","DOI":"10.1371\/journal.pone.0208837","article-title":"Burden and cost of multiple sclerosis in Brazil","volume":"14","author":"G Kobelt","year":"2019","journal-title":"PLoS One"},{"key":"pone.0229768.ref029","first-page":"16","article-title":"Cost analysis of multiple sclerosis in Brazil: a cross-sectional multicenter study","author":"Takemoto MLS Silva NL da","year":"2016","journal-title":"BMC Health Serv Res"},{"key":"pone.0229768.ref030","first-page":"735","article-title":"Hospital admissions and MS: temporal trends and patient characteristics","volume":"18","author":"C Evans","year":"2012","journal-title":"Am J Manag Care"},{"key":"pone.0229768.ref031","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000310301","article-title":"Socioeconomic trends in hospitalization for multiple sclerosis","volume":"35","author":"SP Lad","year":"2010","journal-title":"Neuroepidemiology"},{"key":"pone.0229768.ref032","first-page":"229","article-title":"All-cause hospitalizations in multiple sclerosis patients","volume":"68","author":"C Maia","year":"2019","journal-title":"Rev Neurol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0229768","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:01:52Z","timestamp":1695859312000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0229768"}},"subtitle":[],"editor":[{"given":"Marcello","family":"Moccia","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,3,2]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0229768","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,2]]}}}